Legal & General Group
DRNA

Legal & General Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Legal & General Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60,386
Closed -$1.22M – 3594
2021
Q3 		$1.22M Buy
60,386
+44,332
+276% +$1.22M ﹤0.01% 2190
2021
Q2 		$599K Buy
16,054
+1,658
+12% +$50.8K ﹤0.01% 2307
2021
Q1 		$369K Sell
14,396
-295
-2% -$7.54K ﹤0.01% 2349
2020
Q4 		$323K Sell
14,691
-92
-0.6% -$2.03K ﹤0.01% 2333
2020
Q3 		$265K Sell
14,783
-2,862
-16% -$59.3K ﹤0.01% 2312
2020
Q2 		$448K Buy
17,645
+2,088
+13% +$45K ﹤0.01% 2198
2020
Q1 		$286K Sell
15,557
-2,251
-13% -$43.8K ﹤0.01% 2202
2019
Q4 		$392K Buy
17,808
+4,142
+30% +$83.4K ﹤0.01% 2268
2019
Q3 		$196K Buy
13,666
+4,017
+42% +$57.4K ﹤0.01% 2353
2019
Q2 		$152K Hold
9,649
– – ﹤0.01% 2424
2019
Q1 		$141K Buy
9,649
+463
+5% +$5.32K ﹤0.01% 2402
2018
Q4 		$98K Buy
9,186
+2,561
+39% +$33.7K ﹤0.01% 2465
2018
Q3 		$101K Hold
6,625
– – ﹤0.01% 2509
2018
Q2 		$81K Buy
+6,625
New +$83.2K ﹤0.01% 2555

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Legal & General Group's DRNA Position: Q4 2021 in Review

Legal & General Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 60,386 shares — an estimated $1.22M sold.

Legal & General Group first reported a position in DRNA in Q2 2018 and held it in 14 quarters. The position peaked at $1.22M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Legal & General Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Legal & General Group sold 60,386 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.22M.
  • Legal & General Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
  • Legal & General Group's Dicerna Pharmaceuticals, Inc. position peaked at $1.22M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Legal & General Group's 13F filing for Q4 2021, filed 14 Feb 2022.